PubMed · 2015 · 18 citations · 4 references
PharmacyInternal MedicinePharmacotherapyAllergyImmunotherapyRespiratory PharmacotherapyAsthma ManagementAsthma PharmacotherapyBronchodilator TherapyAsthma Bronchodilator TherapyBiologic Therapy For AsthmaModifying FactorsOmalizumab TherapyPulmonary ExacerbationsSevere Asthma ExacerbationSevere Asthma ManagementSevere Asthma Treatment
Severe asthma, which is poorly controlled despite the elimination of modifiable factors and the correct use of standard therapy, accounts only for 5% of people with asthma but it contributes to approximately 50% of the economic costs of asthma. Because of this unmet need, novel therapies have been developed for optimal treatment of these patients. The use of tiotropium, omalizumab, mepolizumab and thermoplasty in well-selected patients provides better control and most importantly a reduction in asthma exacerbations.
4
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Héctor Ortega, Mark C. Liu, Ian Pavord et al. · New England Journal of Medicine · 2014 · 2.3K citations · Full text
Costs of asthma according to the degree of severity
Joan Serra-Batllés, Vicente Plaza, E. Morejón et al. · European Respiratory Journal · 1998 · 389 citations · Full text
Cost of asthma in the Asia-Pacific region
C. K. W. Lai, Y-Y. Kim, Sung‐Hsin Kuo et al. · European Respiratory Review · 2006 · 63 citations · Full text